New Research in Over 3,700 Patients Treated With World’s First and Only Swallowable Gastric Balloon Program Reveals Weight Loss of Over 14% Total Body Weight

Weight loss of 10-15% now recognized as sufficient to put Type 2 diabetes into remission

NATICK, Mass.–(BUSINESS WIRE)–A study conducted in 3,716 patients from 26 centers across 9 countries treated with the Allurion swallowable gastric balloon and lifestyle program revealed an average Total Body Weight Loss (TBWL) of 14.1% after just four months. The study is the largest of its kind ever conducted and reports a weight loss that is now recognized as sufficient to put patients into remission of Type 2 diabetes.

The Allurion Program — which consists of the world’s first and only gastric balloon which requires no surgery, no endoscopyⁱ and no anaesthesia alongside a fully supported lifestyle program — was also found to significantly improve metabolic parameters, with a consistent safety profile in a diverse, global population.

The study, presented by Dr. Roberta Ienca at Obesity Week in San Diego, also concluded that the Allurion Program’s unique Virtual Care Suite — a remote patient monitoring system and telehealth platform that enables ongoing support in nutrition, behaviour change, activity and healthy sleep patterns — also contributes to improved outcomes.

This study provides further evidence to support the broader metabolic benefits of the Allurion Program. A previous study in 226 patients with Type 2 diabetes and prediabetes demonstrated that on average, the Allurion Program brought both diseases into remissionⁱⁱ.

“With an average weight loss of 14% in just four months across nearly 4,000 patients, the Allurion Program has once again been shown to deliver life-changing results across a broad population,” says Dr. Shantanu Gaur, co-founder and CEO of Allurion. “With weight loss of 10-15% now recognized as a driver for diabetes remission, it is clear that the Allurion Program now has a much wider role to play in metabolic health.”

Presented ahead of World Diabetes Day, this study follows a new consensus report published last month by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) which recommended the need for a greater emphasis on weight loss as part of a holistic approach to diabetes management.

The consensus report confirmed that a weight loss of 5–15% should be a primary target of management for many people living with Type 2 Diabetesⁱⁱⁱ and a higher magnitude of weight loss confers better outcomes. Weight loss of 5–10% confers metabolic improvement and a weight loss of 10–15% or more can have a disease-modifying effect and lead to remission of diabetes^iv.

“Obesity and Type 2 Diabetes are pandemics of unprecedented magnitude, and they often afflict patients simultaneously. Often, current treatments for obesity and diabetes are not enough or are refused by patients because of their invasive nature. This study further strengthens the growing evidence that the Allurion Program offers a compelling treatment for both conditions” says Dr. Roberta Ienca of Clinica Nuova Villa Claudia in Rome, Italy.

Benoit Chardon, Chief Commercial Officer of Allurion, says this data underscores the wider market opportunity for The Allurion Program.

“The Allurion Program provides patients with an effective tool to reduce hemoglobin A1c (HbA1c) and put both pre-diabetes and Type 2 Diabetes into remission. These results underscore the benefits of the Allurion Program beyond weight loss and highlight how quickly the Allurion Program can have a significant health impact on patients.”

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Gastric Balloon, the world’s first and only swallowable, procedureless* gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for clinicians featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion VCS is now available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

Learn more about Allurion online at www.allurion.com and about the Allurion Virtual Care Suite at www.allurion.com/virtual-care-suite.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Ienca, et al. Presented at obesity week 2022.

___________________________

ⁱ In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal

ⁱⁱ Ienca R, Rosa M, Pagan Pomar AA, Hansoulle J, and Caballero A. Emerging Role of the New Swallowable Gastric Balloon in Type 2 Diabetes and Prediabetes Treatment. Poster 114. Presented at TOS Obesity Week 2021.

ⁱⁱⁱ Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394–405

^iv Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394–405

Contacts

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com